| A Pragmatic Clinical Trial of the WE BEAT Well-Being Education Program in Adolescent Congenital Heart Disease: WE BEAT CHD Study | N/A | Carelon Research | Ann Arbor |
| A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma | — | Children's Oncology Group | Ann Arbor |
| A Study With NVC-001 in Patients With LMNA-related Dilated Cardiomyopathy (SUNBEAM-LMNA) | Phase 1/2 | Nuevocor Pte. Ltd. | Ann Arbor |
| A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections | Phase 3 | X4 Pharmaceuticals | Ann Arbor |
| A Study to Assess Real-world Patient Characteristics and Clinical Course for Symptomatic Patients With PKP2-ACM | — | Lexeo Therapeutics | Ann Arbor |
| A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction | Phase 3 | Bayer | Ann Arbor |
| A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction | Phase 3 | Bayer | Ann Arbor |
| ADAPT Micro-Randomized Trial | N/A | University of Michigan | Ann Arbor |
| AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions | N/A | Boston Scientific Corporation | Ann Arbor |
| ARTIST: Aortic Regurgitation Trial Investigating Surgery Versus Trilogy™ | N/A | JenaValve Technology, Inc. | Ann Arbor |
| ATLAS (AltaValve) Pivotal Trial | N/A | 4C Medical Technologies, Inc. | Ann Arbor |
| ATrial Tachycardia PAcing Therapy in Congenital Heart | — | Ian Law | Ann Arbor |
| Abatacept in Immune Checkpoint Inhibitor Myocarditis | Phase 3 | Massachusetts General Hospital | Ann Arbor |
| Ablation-Index Guided Scar-Mediated Ventricular Tachycardia Ablation in Patients With Ischemic Cardiomyopathy | N/A | Rush University Medical Center | Ann Arbor |
| Alleviant ALLAY-HF Study | N/A | Alleviant Medical, Inc. | Ann Arbor |
| Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG | Phase 3 | Icahn School of Medicine at Mount Sinai | Ann Arbor |
| Anticoagulation in ICH Survivors for Stroke Prevention and Recovery | Phase 3 | Yale University | Ann Arbor |
| Assessment of CCM in HF With Higher Ejection Fraction | N/A | Impulse Dynamics | Ann Arbor |
| BIOTRONIK Investigation of the LivIQ Leadless Pacemaker System | N/A | Biotronik, Inc. | Ann Arbor |
| BOND: Direct Breastfeeding to Enhance Maternal and Infant Health in Congenital Heart Disease | N/A | Carelon Research | Ann Arbor |
| BoxX-NoAF Clinical Trial | N/A | AtriCure, Inc. | Ann Arbor |
| CAPTURE-2: Controlled Arterial Protection to Ultimately Remove Embolic Material | N/A | EmStop Inc | Ann Arbor |
| CCM OPEN HF Registry | — | Impulse Dynamics | Ann Arbor |
| CSP #2025 - Geriatric OUt-of-hospital Randomized MEal Trial in Heart Failure: Veterans Affairs (GOURMET-VA) | N/A | VA Office of Research and Development | Ann Arbor |
| Cardiac Sarcoidosis Randomized Trial | Phase 3 | Ottawa Heart Institute Research Corporation | Ann Arbor |
| Cardiovascular Health Improvement Project | — | University of Michigan | Ann Arbor |
| CellFX® Nanosecond Pulsed Field Ablation (nsPFA)™ Cardiac Surgery Clamp System to Treat Atrial Fibrillation | N/A | Pulse Biosciences, Inc. | Ann Arbor |
| Cephea Early Feasibility Study | N/A | Abbott Medical Devices | Ann Arbor |
| Coherent Sine Burst Electroporation (CSE) Ablation System US IDE Study for Patients With Atrial Fibrillation | N/A | Arga Medtech SA | Ann Arbor |
| Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women | N/A | Weill Medical College of Cornell University | Ann Arbor |
| Danon Disease Natural History Study | — | Rocket Pharmaceuticals Inc. | Ann Arbor |
| Designing and Assessing a Women Only Cardiac Rehabilitation (CARE) Program | N/A | University of Michigan | Ann Arbor |
| Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure | N/A | Procyrion | Ann Arbor |
| Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial | N/A | Edwards Lifesciences | Ann Arbor |
| Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II | N/A | Shockwave Medical, Inc. | Ann Arbor |
| Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036) | Phase 2/3 | Merck Sharp & Dohme LLC | Ann Arbor |
| Feasibility of the SCD in Cardiorenal Syndrome Patients Awaiting LVAD | N/A | SeaStar Medical | Ann Arbor |
| Fontan Udenafil Exercise Longitudinal Assessment Trial - 2 | Phase 3 | Mezzion Pharma Co. Ltd | Ann Arbor |
| GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients With Patent Foramen Ovale (PFO): the REDUCE Post Approval Study | N/A | W.L.Gore & Associates | Ann Arbor |
| Groundbreaking Renal Assist Device Intervening to ENhance cardioThoracic Surgery Outcomes | N/A | 3ive Labs | Ann Arbor |
| HCMR Re-Imaging Study | — | Christopher Kramer | Ann Arbor |
| Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy | Phase 4 | Dennis M. McNamara, MD, MS | Ann Arbor |
| Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure | N/A | BrioHealth Solutions, Inc. | Ann Arbor |
| Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk | Phase 3 | Population Health Research Institute | Ann Arbor |
| MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM) | Phase 3 | Intellia Therapeutics | Ann Arbor |
| Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity | Phase 3 | Amgen | Ann Arbor |
| Mechanistic Clinical Trial Comparing the Pharmacokinetics/Pharmacodynamics of Metoprolol in Heart Failure With Reduced Ejection Fraction Patients With Low vs. High Polygenic Score | Phase 4 | University of Michigan | Ann Arbor |
| Medtronic Cardiac Surgery PMCF Registry | — | Medtronic Cardiac Surgery | Ann Arbor |
| Mobile Health Intervention to Increase Activity in Heart Failure Study | N/A | University of Michigan | Ann Arbor |
| National Collaborative to Improve Care of Children With Complex Congenital Heart Disease | — | Children's Hospital Medical Center, Cincinnati | Ann Arbor |
| Optimal Pediatric Heart Transplant Immunosuppression With MicroRNAs | — | Northwestern University | Ann Arbor |
| Pediatric Influence of Cooling Duration on Efficacy in Cardiac Arrest Patients (P-ICECAP) | N/A | University of Michigan | Ann Arbor |
| Percutaneous Intervention Versus Observational Trial of Arterial Ductus in Low Weight Infants | N/A | Nationwide Children's Hospital | Ann Arbor |
| Prehabilitation Program to Improve Cardiac Reserve in High-Risk Patients Undergoing Hematopoietic Stem Cell Transplantation | N/A | University of Michigan Rogel Cancer Center | Ann Arbor |
| Prenatally-initiated Psychological Intervention for Mothers of Infants With Congenital Heart Disease (CHD) | N/A | Carelon Research | Ann Arbor |
| Prevail Global Study | N/A | Medtronic Vascular | Ann Arbor |
| Product Surveillance Registry | — | Medtronic | Ann Arbor |
| REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE | — | Medtronic Cardiovascular | Ann Arbor |
| Reducing Risk for Infective Endocarditis | N/A | Wake Forest University Health Sciences | Ann Arbor |
| S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity | Phase 3 | SWOG Cancer Research Network | Ann Arbor |
| Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure | N/A | Boston Scientific Corporation | Ann Arbor |
| Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | Phase 3 | AstraZeneca | Ann Arbor |
| TVMR With the INNOVALVE System Trial - Early Feasibility Study | N/A | Edwards Lifesciences | Ann Arbor |
| The Choice of Vasopressor to Prevent Postoperative Acute Kidney Injury After Major Non-Cardiac Surgery | Phase 4 | University of California, San Francisco | Ann Arbor |
| The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR | N/A | Cardiac Dimensions, Inc. | Ann Arbor |
| The Fourth Left Atrial Appendage Occlusion Study | N/A | Hamilton Health Sciences Corporation | Ann Arbor |
| The TRICURE EFS Study | N/A | TRiCares | Ann Arbor |
| The WiSE®-UP Study (The WiSE System Utilization & Performance Study) | — | EBR Systems, Inc. | Ann Arbor |
| Tracking Results of Ablations to Combat AF Registry Generation 2 | — | AtriCure, Inc. | Ann Arbor |
| Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation. | N/A | Medtronic Cardiovascular | Ann Arbor |
| Valved Graft PMCF Study | — | Abbott Medical Devices | Ann Arbor |
| WIN Ratio Analysis to Determine a Strategy of Non- Invasive SUpport for Respiratory Failure in the EmeRgency Department | N/A | Ohio State University | Ann Arbor |
| Evaluation of the Efficacy and Safety of THRV-1268 in Participants With Long QT Syndrome Type 2 (LQTS2) and Type 3 (LQTS3) | Phase 2/3 | Thryv Therapeutics, Inc. | Arbor |
| Ask Questions About Clinical Trials | N/A | Barbara Ann Karmanos Cancer Institute | Bay City |
| Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS | Phase 3 | DalCor Pharmaceuticals | Bay City |
| A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity | Phase 3 | Novo Nordisk A/S | Bloomfield Hills |
| A Study to Evaluate the Efficacy, Safety, Pharmacodynamics (PD), and Pharmacokinetics (PK) of Selnoflast in Reducing Vascular Inflammation in Participants With Atherosclerosis at Risk for Major Adverse Cardiac Events | Phase 2 | Genentech, Inc. | Bloomfield Hills |
| A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart | Phase 3 | Boehringer Ingelheim | Bloomfield Hills |
| A Trial of CRD-4730 in HFrEF | Phase 2 | Cardurion Pharmaceuticals, Inc. | Bloomfield Hills |
| Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation | Phase 3 | Regeneron Pharmaceuticals | Bloomfield Hills |
| Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable | Phase 3 | Regeneron Pharmaceuticals | Bloomfield Hills |
| A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure | Phase 3 | Boehringer Ingelheim | Dearborn |
| SuperSaturated Oxygen Comprehensive Observational Registry | — | TherOx | Dearborn |
| Clinical Safety and Efficacy of the VDyne Transcatheter Tricuspid Valve Replacement System for the Treatment of Tricuspid Regurgitation ( VISTA-US) | N/A | VDyne, Inc. | Detriot |
| A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis | Phase 2 | Novartis Pharmaceuticals | Detroit |
| A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events | N/A | Cleerly, Inc. | Detroit |
| A Randomized Placebo-procedure Controlled Trial of the Enhancor System (PULmonary Artery Denervation) to Evaluate Safety and Efficacy in Patients With Combined Pre- and Post-capillary Pulmonary Hypertension Associated With Left Heart Disease | N/A | Pulnovo Medical, Inc. | Detroit |
| A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy | Phase 2 | Novo Nordisk A/S | Detroit |
| A Study of LY3971297 in Participants With Heart Failure | Phase 1 | Eli Lilly and Company | Detroit |
| A Study to Test How Well BAY 3670549 Works and How Safe it is in Patients With Atrial Fibrillation | Phase 2 | Bayer | Detroit |
| AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor | — | Peerbridge Health, Inc | Detroit |
| ALLIANCE AVIV: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve in Failing Aortic Bioprosthetic Valves | N/A | Edwards Lifesciences | Detroit |
| ALLIANCE: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve | N/A | Edwards Lifesciences | Detroit |
| AMBITION 7: A Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight Compared to Insulin Glargine in People With Type 2 Diabetes and Increased Risk of Diseases That Affect the Heart and Blood Vessels Treated With 1-3 Other Diabetes Medications | Phase 3 | Novo Nordisk A/S | Detroit |
| Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant | Phase 3 | Eidos Therapeutics, a BridgeBio company | Detroit |
| CARE-CP (Testing a Cardiovascular Ambulatory Rapid Evaluation for Patients With Chest Pain) | N/A | Wake Forest University Health Sciences | Detroit |
| Central Apnea in Heart Failure: Physiological Mechanisms to Inform Treatment | Phase 4 | VA Office of Research and Development | Detroit |
| Comparative Effectiveness of Carvedilol Versus Metoprolol Succinate in Heart Failure Patients With an Implantable Cardioverter Defibrillator | Phase 4 | University of Rochester | Detroit |
| Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment | — | Children's Oncology Group | Detroit |
| Home-Based Exercise Program Using Mobile Technology After Left Ventricular Assist Device Implantation | N/A | University of Pennsylvania | Detroit |
| IVUS CHIP UPP Registry | — | ECRI bv | Detroit |
| Innoventric Trillium™ Stent Graft Early Feasibility Study (EFS) | N/A | Innoventric LTD | Detroit |
| OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events | Phase 3 | Amgen | Detroit |
| PARTNER 3 Trial - Aortic Valve-in-Valve | N/A | Edwards Lifesciences | Detroit |
| Perioperative Anticoagulant Use for Surgery Evaluation -2 (PAUSE-2) Study Patients Receiving a Direct Oral Anticoagulant (DOACs-Dabigatran, Rivaroxaban, Apixaban or Edoxaban) and Needing Elective High-Bleed-Risk Surgery or an Invasive Procedure | N/A | McMaster University | Detroit |
| Perioperative Anticoagulant Use for Surgery Evaluation -Virtual Visit (PAUSE-Virtual) | — | McMaster University | Detroit |
| Pivotal Study of the SUpira System in Patients Undergoing High-Risk Percutaneous COronaRy InTervention (HRPCI) | N/A | Supira Medical | Detroit |
| Pre-Emptive LAVA-ECMO for Complex High-Risk TAVR | — | Atlantic Health System | Detroit |
| Project 4: ACHIEVE PATHFINDER | N/A | Henry Ford Health System | Detroit |
| Prospective Global Registry for the Study of Chronic Total Occlusion Intervention | — | Minneapolis Heart Institute Foundation | Detroit |
| Real-world Experience of Catheter Ablation for the Treatment of Arrhythmias | — | Heart Rhythm Clinical and Research Solutions, LLC | Detroit |
| Safety and Effectiveness of the Orsiro Mission 48-mm Sirolimus Eluting Coronary Stent System in Subjects With Coronary Artery Lesions | N/A | Teleflex | Detroit |
| Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction | Phase 3 | Cytokinetics | Detroit |
| TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy | Phase 3 | Alnylam Pharmaceuticals | Detroit |
| The PIVATAL Study -Study of Ventricular Arrhythmia (VTA) Ablation in Left Ventricular Assist Device (LVAD) Patients | Phase 4 | University of Rochester | Detroit |
| The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation | Phase 3 | Johns Hopkins University | Detroit |
| Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR | N/A | EnCompass Technologies, Inc. | Detroit |
| Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure | N/A | Abbott Medical Devices | Detroit |
| UPBEAT: Using Polygenic Scores to Guide BB Therapy in HF With Mildly Reduced EF | N/A | David Lanfear | Detroit |
| A Study to See if Lepodisiran Can Reduce Plaque in Coronary Arteries of Adults With Elevated Lp(a) Who Have Had Heart Events or Are at High Risk | Phase 3 | Eli Lilly and Company | Farmington Hills |
| Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin | Phase 3 | AstraZeneca | Farmington Hills |
| Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation | Phase 2 | Regeneron Pharmaceuticals | Farmington Hills |
| A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF | Phase 3 | AstraZeneca | Flint |
| A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM) | — | Bristol-Myers Squibb | Grand Rapids |
| A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy | Phase 2 | Imbria Pharmaceuticals, Inc. | Grand Rapids |
| Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i Registry | — | Leiden University Medical Center | Grand Rapids |
| AngelMed Guardian® System PMA Post Approval Study | — | Angel Medical Systems | Grand Rapids |
| Medtronic Terminate AF Study | N/A | Medtronic Cardiac Surgery | Grand Rapids |
| PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III | N/A | Endotronix, Inc. | Howell |
| Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD) | Phase 2/3 | CSL Behring | Kalamazoo |
| Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention | Phase 4 | Duke University | Lansing |
| Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products | — | Medtronic | Lansing |
| Staged Complete Revascularization for Coronary Artery Disease vs Medical Management Alone in Patients With AS Undergoing Transcatheter Aortic Valve Replacement | N/A | University of British Columbia | Lansing |
| Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76) | Phase 3 | Anthos Therapeutics, Inc. | Lansing |
| The Long-term Safety and Effectiveness Evaluation of the QDOT MICRO System Use in Conjunction With VISITAG SURPOINT Module for the Treatment of Symptomatic Drug Refractory Paroxysmal Atrial Fibrillation. | — | Heart Rhythm Clinical and Research Solutions, LLC | Lansing |
| Lifewise Preventive Video Education in Primary Care | N/A | Trinity Health-Livonia | Livonia |
| Severe Complications During Ventricular Tachycardia or Premature Ventricular Complex Ablation | — | University Hospital, Basel, Switzerland | Michigan Center |
| Focused Orticumab Research for Treating Inflammation in Coronary Arteries | Phase 2 | Abcentra | Midland |
| Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study | Phase 2/3 | Kardigan, Inc. | Royal Oak |
| Investigational Trial to Evaluate XC001 Delivered Via an Cardiac Catheter in Subjects With Chronic Angina. | Phase 2 | XyloCor Therapeutics, Inc. | Royal Oak |
| PULSED AF Post-Approval Study | — | Medtronic Cardiac Ablation Solutions | Royal Oak |
| Valve Hemodynamic Optimization Based on Doppler-Echocardiography vs Catheterization Measurements Following ViV TAVR | N/A | Institut universitaire de cardiologie et de pneumologie de Québec, University Laval | Royal Oak |
| Virtue® SAB in the Treatment of Coronary ISR Trial | N/A | Orchestra BioMed, Inc | Royal Oak |
| Minima Stent System Post- Approval Study (PAS) | — | Renata Medical | Saint Louis |
| A Study Assessing Long-Term Safety and Effectiveness in Treatment Management of Atrial Fibrillation With VARIPULSE Catheter System | N/A | Biosense Webster, Inc. | Ypsilanti |
| A Study of EDG-15400 in Adults With Heart Failure With Preserved Ejection Fraction (EQUINOX-HFpEF) | Phase 2 | Edgewise Therapeutics, Inc. | Ypsilanti |
| Multi-Center Study of Clinical and Inflammatory Outcomes in Intensive Cardiac Rehabilitation and Traditional Cardiac Rehabilitation Programs | N/A | Pritikin ICR | Ypsilanti |
| Repeatable Evaluation of Functional Intra-procedural Signals for Effect in Pulsed Field Ablation REFINE-PFA | — | CathVision ApS | Ypsilanti |